Cargando…

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage

BACKGROUND: Inflammation plays an essential role in secondary brain injury after intracerebral hemorrhage (ICH). Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have been suggested to suppress neuroinflammation after central nervous system (CNS) damage in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chao, Zhong, Jun, Chen, Wei-Xiang, Zhang, Xu-Yang, Li, Yu-Hong, Zhou, Teng-Yuan, Zou, Yong-Jie, Lan, Chuan, Li, Lan, Lai, Zhao-Pan, Feng, Hua, Hu, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881796/
https://www.ncbi.nlm.nih.gov/pubmed/33603374
http://dx.doi.org/10.2147/NDT.S291624
_version_ 1783650952309374976
author Zhang, Chao
Zhong, Jun
Chen, Wei-Xiang
Zhang, Xu-Yang
Li, Yu-Hong
Zhou, Teng-Yuan
Zou, Yong-Jie
Lan, Chuan
Li, Lan
Lai, Zhao-Pan
Feng, Hua
Hu, Rong
author_facet Zhang, Chao
Zhong, Jun
Chen, Wei-Xiang
Zhang, Xu-Yang
Li, Yu-Hong
Zhou, Teng-Yuan
Zou, Yong-Jie
Lan, Chuan
Li, Lan
Lai, Zhao-Pan
Feng, Hua
Hu, Rong
author_sort Zhang, Chao
collection PubMed
description BACKGROUND: Inflammation plays an essential role in secondary brain injury after intracerebral hemorrhage (ICH). Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have been suggested to suppress neuroinflammation after central nervous system (CNS) damage in animal models. However, the role of ACEIs and ARBs in ICH patients with hypertension remains unresolved in clinic. The aim of the present study is to evaluate the effect of ACEIs/ARBs on ICH patients with hypertension using a retrospective, single-center data analysis. METHODS: ICH patients diagnosed by computerized tomographic (CT) at Southwest Hospital, Third Military Medical University were included in the present research from January 2015 to December 2019. According to the medical history for the usage of antihypertensive drugs, patients were assigned into either ACEIs/ARBs group or non-ACEIs/ARBs group. Demographics, clinical baseline, radiological documents and treatments were collected and these data were statistically analyzed between the two groups. RESULTS: A total of 635 ICH patients with hypertension were included and allocated into 2 groups according to the usage of antihypertensive drugs: 281 in the ACEIs/ARBs group and 354 in the non-ACEIs/ARBs group. The results presented that the 3-months mortality and prevalence of ICH-associated pneumonia were lower in ACEIs/ARBs group than that in non-ACEIs/ARBs group (5.0% vs 11.9%, p=0.002; 58.4% vs 66.7%, p=0.031). While, there was no significant difference in favorable outcome (40.2% vs 33.9%, p=0.101) between the two groups. Furthermore, patients in ACEIs/ARBs group exhibited significantly less perihematomal edema volume on days 3 (23.5 ± 14.4 versus 28.7 ± 20.1 mL, p=0.045) and 7 (21.0 ± 13.7 versus 25.7 ± 17.6 mL, p=0.044), compared to that in non- ACEIs/ARBs group. CONCLUSION: The usage of ACEIs/ARBs helps decrease mortality, perihematomal edema volume, and prevalence of ICH-associated pneumonia in ICH patients with hypertension.
format Online
Article
Text
id pubmed-7881796
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78817962021-02-17 Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage Zhang, Chao Zhong, Jun Chen, Wei-Xiang Zhang, Xu-Yang Li, Yu-Hong Zhou, Teng-Yuan Zou, Yong-Jie Lan, Chuan Li, Lan Lai, Zhao-Pan Feng, Hua Hu, Rong Neuropsychiatr Dis Treat Original Research BACKGROUND: Inflammation plays an essential role in secondary brain injury after intracerebral hemorrhage (ICH). Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have been suggested to suppress neuroinflammation after central nervous system (CNS) damage in animal models. However, the role of ACEIs and ARBs in ICH patients with hypertension remains unresolved in clinic. The aim of the present study is to evaluate the effect of ACEIs/ARBs on ICH patients with hypertension using a retrospective, single-center data analysis. METHODS: ICH patients diagnosed by computerized tomographic (CT) at Southwest Hospital, Third Military Medical University were included in the present research from January 2015 to December 2019. According to the medical history for the usage of antihypertensive drugs, patients were assigned into either ACEIs/ARBs group or non-ACEIs/ARBs group. Demographics, clinical baseline, radiological documents and treatments were collected and these data were statistically analyzed between the two groups. RESULTS: A total of 635 ICH patients with hypertension were included and allocated into 2 groups according to the usage of antihypertensive drugs: 281 in the ACEIs/ARBs group and 354 in the non-ACEIs/ARBs group. The results presented that the 3-months mortality and prevalence of ICH-associated pneumonia were lower in ACEIs/ARBs group than that in non-ACEIs/ARBs group (5.0% vs 11.9%, p=0.002; 58.4% vs 66.7%, p=0.031). While, there was no significant difference in favorable outcome (40.2% vs 33.9%, p=0.101) between the two groups. Furthermore, patients in ACEIs/ARBs group exhibited significantly less perihematomal edema volume on days 3 (23.5 ± 14.4 versus 28.7 ± 20.1 mL, p=0.045) and 7 (21.0 ± 13.7 versus 25.7 ± 17.6 mL, p=0.044), compared to that in non- ACEIs/ARBs group. CONCLUSION: The usage of ACEIs/ARBs helps decrease mortality, perihematomal edema volume, and prevalence of ICH-associated pneumonia in ICH patients with hypertension. Dove 2021-02-09 /pmc/articles/PMC7881796/ /pubmed/33603374 http://dx.doi.org/10.2147/NDT.S291624 Text en © 2021 Zhang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhang, Chao
Zhong, Jun
Chen, Wei-Xiang
Zhang, Xu-Yang
Li, Yu-Hong
Zhou, Teng-Yuan
Zou, Yong-Jie
Lan, Chuan
Li, Lan
Lai, Zhao-Pan
Feng, Hua
Hu, Rong
Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
title Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
title_full Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
title_fullStr Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
title_full_unstemmed Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
title_short Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
title_sort usage of angiotensin-converting enzyme inhibitor or angiotensin ii receptor blocker in hypertension intracerebral hemorrhage
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881796/
https://www.ncbi.nlm.nih.gov/pubmed/33603374
http://dx.doi.org/10.2147/NDT.S291624
work_keys_str_mv AT zhangchao usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage
AT zhongjun usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage
AT chenweixiang usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage
AT zhangxuyang usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage
AT liyuhong usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage
AT zhoutengyuan usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage
AT zouyongjie usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage
AT lanchuan usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage
AT lilan usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage
AT laizhaopan usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage
AT fenghua usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage
AT hurong usageofangiotensinconvertingenzymeinhibitororangiotensiniireceptorblockerinhypertensionintracerebralhemorrhage